Immune imprinting and SARS-CoV-2 vaccine design

[1]  A. García-Sastre,et al.  Immunological imprinting of the antibody response in COVID-19 patients , 2021, Nature Communications.

[2]  C. Swanton,et al.  Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination , 2021, The Lancet.

[3]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[4]  L. Ma,et al.  Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster , 2021, medRxiv.

[5]  H. van Bakel,et al.  The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD , 2021, medRxiv.

[6]  S. Kent,et al.  Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques , 2021, Nature Communications.

[7]  D. Stuart,et al.  The antigenic anatomy of SARS-CoV-2 receptor binding domain , 2021, Cell.

[8]  D. Stuart,et al.  ­­­The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain , 2020, SSRN Electronic Journal.

[9]  John D. Davis,et al.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[10]  D. Bernstein,et al.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial , 2020, Nature Medicine.

[11]  J. Yewdell,et al.  Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem , 2019, The Journal of clinical investigation.

[12]  Nicholas S. Kelley,et al.  Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. , 2016, The Lancet. Infectious diseases.

[13]  J. Mascola,et al.  Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.

[14]  C. A. Russell,et al.  Antibody landscapes after influenza virus infection or vaccination , 2014, Science.

[15]  F. M. Davenport,et al.  PREDETERMINATION BY INFECTION AND BY VACCINATION OF ANTIBODY RESPONSE TO INFLUENZA VIRUS VACCINES , 1957, The Journal of experimental medicine.